Table 3.

Adverse events according to the intention-to-treat population.

	ATT group (N = 37)		Control group (N = 39)
	N events	Percentage (%)	N events	Percentage (%)
Drug-induced liver injury (DILI)	1	2.7%	0	0
Dyspepsia or gastritis	7	18.9%	1	2.6%
Rectal bleeding	0	0	1	2.6%
Chronic fatigue	0	0	1	2.6%
Intolerable Cushing's syndrome	0	0%	1	2.6%
Skin lesions/hypersensitivity reaction	2	5.4%	1	2.6%
Elevated uric acid level	3	8.1%	0	0
Total	13	35.1%	5	12.8%